3D printing food products for personalised sport nutrition

3DWaxForm vil udvikle en radikal ny tilgang til støbeformsfremstilling, og hermed skabe cirkulær, prisbillig fremstilling af avancerede betonkonstruktioner, i hvilken forskallingsaffald elimineres. Ved at udnytte den veldokumenterede, men indtil nu forbigåede egenskab ved maskinvoks, at det danner et formbart legeme i faseskiftet fra flydende til hærdet tilstand, foreslår projektet en revolutionerende ny metode for storskala højhastigheds 3d-print af voks-baserede støbeforme til beton

Novel sperm harvester and sperm multiparametric analyser for male fertility diagnosis

4Mvideo E-sport cycling at home for rehabilitation and daily exercise purposes

Infertility is a common issue often treated with assisted reproductive techniques (ART). We have shown that presence of the vitamin D inactivating enzyme (CYP24A1) in sperm is a positive predictive marker of semen quality. Our aim is to determine if CYP24A1 expression can predict if a mild or invasive ART should be used and elucidate where spermatozoa encounter vitamin D. Ultimately, the project may optimize fertility treatment of benefit for infertile couples, the health care system and society

Novo Nordisks patienter er dybt afhængige af at have adgang til innovative devices med høj pålidelighed. Øget brug af varians-baserede simuleringer i udviklingsprocessen ville kunne give design ingeniørerne en øget forståelse af hvordan devicet vil fungere i hele udfaldsområdet, dvs. inkl. varians fra produktion og brug. Udvikling af en proces og metoder til at lave sådanne simuleringer vil muliggøre hurtig udvikling af innovative og pålidelige devices, hvilket kommer patienterne til gode.

I samarbejde med Innovationsfonden vil Deon Digital Denmark A/S og København Universitet med dette projekt opnå konceptualisering, design, implementering og rigorøs evaluering af en platform til håndtering af smarte, digitale og decentraliserede obligationskontrakters livscyklus. Dette vil innovere på den seneste forskning inden for skalering af Blockchains og vil styrke dansk Blockchain forskning ved at levere videnskabeligt baseret dataforvaltningsteknologi til håndtering af disse kontrakter.

Many antibiotic-resistant infections are caused by bacterial biofilms. In the biofilm form, bacteria survive exposure to highest deliverable doses of antibiotics. This project aims to devise an intervention strategy fundamentally different to current scenarios. It is based on the finding that a bacterial signal molecule c-di-GMP controls the biofilm life-cycle in bacteria; high internal levels of c-di-GMP promote biofilm formation and low levels lead to bacterial dispersal and biofilm dismantling. Our strategy is to dismantle infectious biofilms and then subsequently eradicate the liberated, bacteria with conventional antibiotics. We have developed a drug candidate (patent application submitted) that reduces the internal c-di-GMP pool. In essence, we have invented a new type of non-antibiotic antimicrobial that can improve the efficacy of existing antibiotics on antibiotic-resistant infections, in combinatorial interventions. The InnoExplorer grant will provide financial support for mouse-model experiments leading to development of a robust treatment strategy for Catheter-Associated Urinary Tract Infections (CAUTI). This is one of the commonest global hospital-acquired, biofilm-based infections. A large market exists within the CUTI field, at USD5.7billion in the USA alone. Estimates suggest that market shares for a new antibacterial may range from USD4million at Year 1 post-approval to USD 1billion by Year 10. The grant will also provide financial support for early commercialization activity to prepare the funding of a spin out to oversee a Phase 1 clinical trial. At the present stage, we emphasize that failure to do so is also the major risk. Longer-term goals include revenue generation and regional reputation enhancement. This program is expected to generate commercialisable IPR that revolutionizes treatment and prevent of recalcitrant, antibiotic-resistant infections. It will also find application in industrial settings where biofilms and fouling are costly.

Peptider er en lovende klasse af molekyler til behandling af en lang række sygdomme. I nærværende projekt ønsker vi at udvikle en ny peptid-screenings platform som muliggør direkte selektion af enkelte funktionelt aktive peptider fra peptid-biblioteker som indeholder op til milliarder af individuelle peptider. Det forventes at etablering af en sådan screenings platform vil øge mulighederne for hurtigere at finde terapeutiske peptider med nye virkningsmekanismer og ønskede egenskaber.

Biologiske lægemidler har en række unikke egenskaber, der har ført til gennembrud inden for behandling af mange sygdomme. Udviklingen af denne type lægemidler er imidlertid forbundet med store udfordringer, da de aktive lægemiddelstoffer kan være ustabile eller forårsage immunrespons i patienten. I dette projekt adresseres disse problemstillinger gennem udvikling af en ny banebrydende analyseteknologi baseret på tynde kapillarrør. Teknologien vil ultimativt fører til nye og sikrere lægemidler.

Today 12 mil. diabetics inject human insulin with a syringe as modern devices are unaffordable. A durable and disposable combined device is a cost-neutral simple alternative with commercial potential.

Norlase is developing a game-changer multi-scanner pattern laser photocoagulator (PSL) – MAPLE to treat severe eye diseases. Based on the combination of two cutting edge technologies (high-powered direct diode and MEMS) MAPLE will offer key unprecedent low-cost and compactness, while ensuring premium therapeutic efficiency. The Innobooster project will ensure the advanced prototyping and validation of MAPLE, key steps towards the medical market entrance and wide acceptance.

The aim of the project is to develop new antibiotics and prepare one or more candidates for potential commercialization in collaboration with a not yet defined business partner. We base the project on a new compound class, for which we have recently identified pronounced activity against MRSA as well as linezolid- and vancomycin-resistant enterococci (VRE) – genera that already constitute serious threats to human health. Our compound class belongs to the group of pleuromutilin conjugates, which is inherently associated with low rates of resistance and cross-resistance development. The specific class has further superiority as it is chemically different to other pleuromutilin based compounds and moreover easily synthesized. For the compounds to reach the marked as oral formulations, pharmaceutical properties and preclinical in vivo efficacy need to be established. In vitro optimization of pharmacokinetic performance is therefore key together with preclinical in vivo efficacy. For this task, we have a collective of specialized researchers combining medicinal chemistry, microbiology, pharmaceutical technology, and preclinical evaluation. Within a year we expect to have at least one compound within our class that not only has a significant and broad activity against Gram-positive pathogens but is also a drug candidate with sufficient pharmacokinetic profile, low toxicity and validated preclinical effect. Parallel to the experimental approach, we will investigate the commercial potential of the compound class by involving external consultancy. It is our goal to minimize the risks for a future partner by focusing the project on the drug-like properties, and with an optimized compound in hand, we expect to engage in a collaboration with a commercial partner. The antibiotic marked is huge and increasing as the global health problem related to multi-resistant bacteria is growing dramatically. Hereby, the perspectives for a new systemic antibiotic are almost limitless.

The aim of the project is to develop a new humanized psoriasis mouse model with increased translational value compared to the widely used xenograft psoriasis mouse model. The IL-23/IL-17 pathway is known as a key pathway in psoriasis and constitutes a major target in new treatments of psoriasis. Thus, the new translational humanized psoriasis mouse model should present with characteristics of psoriasis, human immune cells and long-term IL-23/IL-17 activity.